Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 08, 2016 16:30 ET | Source: BeiGene Ltd.

BeiGene Announces Closing of Its Initial Public Offering

BEIJING, Feb. 08, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (“BeiGene” or “the Company”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological...
February 02, 2016 21:30 ET | Source: BeiGene Ltd.

BeiGene Announces Pricing of Its Initial Public Offering

BEIJING, Feb. 2, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. ("BeiGene" or "the Company"), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs...
January 08, 2016 13:06 ET | Source: BeiGene Ltd.

U.S. IND Becomes Active for BGB-A317, an Anti-PD-1 Monoclonal Antibody

BEIJING, Jan. 08, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of...
December 07, 2015 18:00 ET | Source: BeiGene Ltd.

BeiGene Presents Clinical Data for BTK Inhibitor BGB-3111 at 57th ASH Annual Meeting

BEIJING, Dec. 7, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
November 17, 2015 08:00 ET | Source: BeiGene Ltd.

BeiGene Receives 2015 R&D Achievement of Year at BayHelix China Pharmaceutical Awards

BEIJING, Nov. 17, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
November 09, 2015 08:00 ET | Source: BeiGene Ltd.

BeiGene Appoints Dr. Zhengming Du as Senior Vice President, Head of Chemistry and Manufacturing Controls

BEIJING, Nov. 9, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
November 02, 2015 08:00 ET | Source: BeiGene Ltd.

BeiGene Announces Appointment of Dr. RuiRong Yuan as Chief Medical Officer and President of Global Clinical Development

BEIJING, Nov. 2, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
October 28, 2015 12:11 ET | Source: BeiGene Ltd.

BeiGene Announces Abstracts to be Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BEIJING, Oct. 28, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
October 12, 2015 10:47 ET | Source: BeiGene Ltd.

BeiGene Doses First Patient in China With BGB-283 for Solid Tumors

BEIJING, Oct. 12, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
September 30, 2015 08:00 ET | Source: BeiGene Ltd.

BeiGene Appoints Changzhen Wu as Head of Manufacturing Operations

BEIJING, Sept. 30, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...